The adjustment in price target by Truist Securities reflects a slightly more positive outlook on Integra Lifesciences, but the Hold rating indicates that the analyst does not see significant short-term price movement. The increase in price target may be viewed positively by the market, but as it is not a change to a Buy rating, the impact is likely to be moderate.